Ventyx Biosciences, Inc.
Net SellingVTYX·US·🇺🇸 US
7%buys·93%sales
464 transactions$71.3MTotal buys·13 buys
$110.5MTotal sells·181 sells
2929 insiders
Last: Dec 18, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 18, 25 | Nuss John | Sell | $98K | |
| Dec 18, 25 | Mohan Raju | Sell | $366K | |
| Dec 17, 25 | Nuss John | Exercise | - | |
| Dec 17, 25 | Mohan Raju | Exercise | - | |
| Dec 17, 25 | Nuss John | Exercise | - | |
| Dec 17, 25 | Mohan Raju | Exercise | - | |
| Nov 17, 25 | Gonzales Roy | Grant | $2K | |
| Nov 17, 25 | Forman Mark S | Grant | $3K | |
| Jun 5, 25 | Gujrathi Sheila | Grant | - | |
| Jun 5, 25 | White William Richard | Grant | - |
Mohan Raju (CEO) recently executed a sell of $366K in Ventyx Biosciences, Inc. shares on December 18, 2025. Overall insider sentiment is bearish (93% sales).
Ventyx Biosciences, Inc. (VTYX) has recorded 464 insider operations, including 13 open-market purchases ($71.3M), 181 sales ($110.5M) and 270 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (93% sales).
Insider activity at Ventyx Biosciences, Inc. is sustained, with operations recorded in 8 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are Mohan Raju (CEO), Auster Martin (CFO) & Krueger Christopher W (C SUITE), with respectively 51, 31, 93 transactions.
Across all 465 recorded transactions, the breakdown by type is: sales (181, 39%), exercise (158, 34%), grant (88, 19%), other (23, 5%), buys (13, 3%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Ventyx Biosciences, Inc. has recorded 464 insider operations in total, including 13 open-market purchases ($71.3M), 181 sales ($110.5M) and 270 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 18, 2025.
Insiders at Ventyx Biosciences, Inc. are currently net sellers, with 7% purchases and 93% sales across all reported transactions. Total buy volume is $71.3M versus $110.5M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 29 insiders at Ventyx Biosciences, Inc. (VTYX). Mohan Raju (CEO, 51 tx), Auster Martin (CFO, 31 tx), Krueger Christopher W (C SUITE, 93 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for VTYX is bearish, based on a 7% buy ratio across 194 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Ventyx Biosciences, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.